Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products
Open Access
- 28 April 2006
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 62 (3), 264-271
- https://doi.org/10.1111/j.1365-2125.2006.02654.x
Abstract
Orphan medicinal products (OMPs) are targeted at the diagnosis, prevention or treatment of rare diseases and have a special status in European law. This status brings incentives for pharmaceutical companies to invest in OMP development. The goal of the legislation is to encourage the development of more treatments for life‐threatening rare disorders, but increased availability of OMPs raises important issues surrounding the public funding of very expensive treatments by national health services. In this article we review OMPs and the incentives for their development and discuss the challenges presented by funding these treatments.This publication has 16 references indexed in Scilit:
- Orphan drug development is progressing too slowlyBritish Journal of Clinical Pharmacology, 2006
- GENETIC POLYMORPHISMS AND SEPSISShock, 2005
- Adopting an orphanEMBO Reports, 2005
- Endothelin antagonism in pulmonary hypertension, heart failure, and beyondHeart, 2005
- Potential Interactions of the Orphan Drug Act and Pharmacogenomics: A Flood of Orphan Drugs and Abuses?American Journal of Law & Medicine, 2005
- EU to review rare disease drugs market exclusivityNature Biotechnology, 2004
- The Rule of RescueSocial Science & Medicine (1982), 2003
- New products highlight ambiguity of orphan drug lawNature Biotechnology, 2003
- Two decades of orphan product developmentNature Reviews Drug Discovery, 2002
- Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of careCritical Care Medicine, 2001